摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,2R,3S,4R,5S)-4-tert-butyl-1-ethyl-5-nitro-3-(pentan-3-yloxy)-2-(p-tolylthio)cyclohexane-1,4-dicarboxylate | 1141364-91-1

中文名称
——
中文别名
——
英文名称
(1S,2R,3S,4R,5S)-4-tert-butyl-1-ethyl-5-nitro-3-(pentan-3-yloxy)-2-(p-tolylthio)cyclohexane-1,4-dicarboxylate
英文别名
(1S,2R,3S,4R,5S)-4-tert-butyl-1-ethyl-5-nitro-3-(3-pentyloxy)-2-(p-tolylthio)cyclohexane-1,4-dicarboxylate;4-O-tert-butyl 1-O-ethyl (1S,2R,3S,4R,5S)-2-(4-methylphenyl)sulfanyl-5-nitro-3-pentan-3-yloxycyclohexane-1,4-dicarboxylate
(1S,2R,3S,4R,5S)-4-tert-butyl-1-ethyl-5-nitro-3-(pentan-3-yloxy)-2-(p-tolylthio)cyclohexane-1,4-dicarboxylate化学式
CAS
1141364-91-1
化学式
C26H39NO7S
mdl
——
分子量
509.664
InChiKey
YQUVUPMCCHIKCG-ISBRNDMJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    582.0±50.0 °C(Predicted)
  • 密度:
    1.16±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    35
  • 可旋转键数:
    12
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.69
  • 拓扑面积:
    133
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • High‐Yielding Synthesis of the Anti‐Influenza Neuraminidase Inhibitor (−)‐Oseltamivir by Two “One‐Pot” Sequences
    作者:Hayato Ishikawa、Takaki Suzuki、Hideo Orita、Tadafumi Uchimaru、Yujiro Hayashi
    DOI:10.1002/chem.201001108
    日期:2010.11.8
    Michael reactions, a thiol Michael reaction, and a base‐catalyzed isomerization. Six reactions can be successfully conducted in the second one‐pot reaction sequence; these are deprotection of a tert‐butyl ester and its conversion into an acyl chloride then an acyl azide, Curtius rearrangement, amide formation, reduction of a nitro group into an amine, and a retro Michael reaction of a thiol moiety. A column‐free
    通过使用两个“一锅”反应序列可实现有效的不对称总合成(-)-oseltamivir(一种抗病毒剂),其总收率极佳(60%),并且仅需通过柱色谱法纯化一次即可。第一个单锅反应序列由二苯基脯氨醇甲硅烷基醚介导的不对称迈克尔反应,多米诺骨牌迈克尔反应/霍纳-沃兹沃思-埃蒙斯反应与逆醛醇/霍纳-沃兹沃斯-埃蒙斯反应和逆迈克尔反应,硫代迈克尔反应组成,以及碱催化的异构化。在第二个“一锅法”反应序列中可以成功进行六个反应。这些都是去保护叔-丁基酯及其转化为酰氯,然后转化为酰叠氮,Curtius重排,酰胺形成,硝基还原为胺以及硫醇基团的逆迈克尔反应。还建立了(-)-奥司他韦的无柱合成方法。
  • High-Yielding Synthesis of the Anti-Influenza Neuramidase Inhibitor (−)-Oseltamivir by Three “One-Pot” Operations
    作者:Hayato Ishikawa、Takaki Suzuki、Yujiro Hayashi
    DOI:10.1002/anie.200804883
    日期:2009.2.2
    Taking shortcuts: A remarkably short and high‐yielding asymmetric total synthesis of ()‐oseltamivir takes advantage of organocatalysis and single‐pot domino operations. The target, known as the drug Tamiflu, is prepared efficiently in a short time, and also its derivatives can be synthesized effectively.
    走捷径:(-)-奥司他韦的明显短且高产的不对称总合成利用了有机催化和单罐多米诺骨牌操作的优势。可以在短时间内有效地制备称为药物达菲的靶标,并且还可以有效地合成其衍生物。
  • PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND
    申请人:Sumitomo Chemical Company, Limited
    公开号:EP2301911B1
    公开(公告)日:2015-08-19
  • Synthesis of (-)-Oseltamivir by Using a Microreactor in the Curtius Rearrangement
    作者:Hayato Ishikawa、Bojan P. Bondzic、Yujiro Hayashi
    DOI:10.1002/ejoc.201100074
    日期:2011.10
    generated isocyanate with a nucleophile was established, which is safe, inexpensive, and suitable for large-scale synthesis. By this flow reaction in the Curtius rearrangement and recrystallization of the late-stage acetamide intermediate the third-generation synthesis of (-)-Oseltamivir has been established, which is efficient, practical, and safe.
    建立了以三甲基甲硅烷基叠氮化物为叠氮化物源,然后用亲核试剂捕获生成的异氰酸酯的 Curtius 重排微流反应,该反应安全、廉价且适合大规模合成。通过库尔提斯重排和后期乙酰胺中间体的重结晶的流动反应,建立了(-)-奥司他韦的第三代合成方法,该方法高效、实用且安全。
  • One-Pot Reactions Accelerate the Synthesis of Active Pharmaceutical Ingredients
    作者:Carine Vaxelaire、Philipp Winter、Mathias Christmann
    DOI:10.1002/anie.201100059
    日期:2011.4.11
    All in one: A one‐pot synthesis of the dipeptidylpeptidase IV selective inhibitor ABT‐341 (see structure) by using an “uninterrupted sequence of reactions” has been developed. This strategy broadens the spectrum of one‐pot reactions and is poised to speed up the synthesis of medicinally relevant drug compounds.
    总而言之:已经开发出了一种通过“不间断的反应顺序”来合成二肽基肽酶IV选择抑制剂ABT-341(参见结构)的方法。该策略拓宽了一锅反应的范围,并有望加快医学上相关药物化合物的合成。
查看更多